Numinus Wellness looking to position itself at the forefront of psychedelics for healing and wellness
Through its Bioscience lab, Numinus is the first public company in Canada to receive a licence to produce and extract psilocybin from mushrooms
Sector
Health
988 stories · page 35 of 50
CareRx Corporation sees 3Q revenue rise by 56%, driven by acquisitions and strong organic growth
For the period ended September 30, 2021, the Toronto-based company reported revenue of C$71.3 million, compared to C$45.6 million in the corresponding period a year earlier
Braxia Scientific CEO McIntyre to join KetaMD as an adviser
KetaMD, currently in beta, is a telemedicine platform in development that aims to provide affordable, potentially life-changing at-home medical ketamine treatments guided by registered nurses
Ketamine One says it intends to submit a draft registration statement for a proposed US IPO
The company also said that it has appointed Director Steven Inglefield as Chief Operating Officer as the company continues to grow its clinic network across Canada and the US
Wellteq Digital Health is establishing one of the world’s leading digital health and wellness platforms
The company expects its Software-as-a-Service (SaaS) revenue for fiscal 2021 to increase by more than 100% year over year
Levitee Labs looking to be world's first listed psychedelic company with significant revenue and cashflow
The company is working swiftly to establish itself as a leader in the integrated wellness and psychedelic medicine market
Ketamine One announces partnership with iHealthOX for telehealth, virtual health services
Under the partnership with iHealthOX, patients will have the option of being virtually assessed by a physician and a clinical health provider to determine their suitability to undergo ketamine therapy
COVID-19: UK infection rates at highest ever recorded level, study shows
The prevalence of infection is 1.72%, compared with 0.83% in September
Braxia Scientific completes psilocybin-assisted therapy training for first cohort of therapists; ready to begin Health Canada-approved clinical trial
Through this program, therapists will be competent to perform psilocybin-assisted therapy in upcoming clinical trials, evaluating the safety and efficacy of psilocybin in depression
Arecor Therapeutics inks its fourth collaboration agreement in six months
It is developing a ready-to-administer product for a leading global medical products company
Wellteq Digital partners with Australia's Monash University to commercialize sleep research, coaching solution for insomnia
The initial commercialization efforts will focus on the aviation, healthcare, mining, and construction sectors, where workers are at heightened risk of excessive sleepiness at work and insomnia at home
Irwin Naturals sets up wholly-owned units to enter US, Canada recreational cannabis market and psychedelic mental health industry
The firm intends to enter the North American cannabis industry by licensing its household brand name to licensed third parties that manufacture products containing tetrahydrocannabinol (THC)
Ketamine One announces changes to shares' listing after spin-out transaction of its subsidiary company
Ketamine One is also working with OTC markets and other applicable regulatory agencies to become ‘15c2-11 Certified’ under Rule 15c2-11 of the Securities and Exchange Commission of the United States
Wellteq Digital Health completes execution of perpetual license agreement with one of Asia Pacific’s leading sleep technology providers
The license agreement centers on sleep chronotype assessments and educational content
Braxia's study on COVID-19 and suicide rates in Canada published in influential journal, urges continued government intervention and timely psychiatric services
The study, titled ‘Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reduction’, suggests public policies and strategies for reducing suicide rates in the country
NA Proactive news snapshot: Nova Royalty, Lucky Minerals, PyroGenesis Canada, GreenBank Capital, Thunderbird Entertainment UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Ketamine One is conducting its inaugural research studies with Biostrap across multiple locations
The observational studies will collect advanced biometric data in upcoming depression and post-traumatic stress disorder studies across locations in Canada and the US
Braxia Scientific CEO Roger McIntyre to join Lamar Odom and Zappy Zapolin in panel discussion on ketamine treatment for mental health
The Wonderland: Miami conference is scheduled to kick off on November 8, inviting multiple companies in the psychedelic space to connect with the psychedelic medicinal space
KetamineOne plans inaugural research studies targeting depression and post-traumatic stress disorder
“Our hope is that both the PTSD Study and the Depression Study yield significant results, which enable not only our clinicians but those in other clinics as well as to improve the patient experience and alleviate chronic pain, depression an
Wellteq Digital Health strikes 3-year contract extension with its largest client, Australia-based nib health funds
nib is Australia’s fourth-largest private health insurer and provides private health insurance coverage to over 1.2 million policyholders